Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating on November 4.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Schwartz has given his Buy rating due to a combination of factors, primarily focusing on uniQure’s ongoing efforts and potential in developing AMT-130 for Huntington’s disease. Despite recent regulatory challenges, Schwartz notes that the data supporting AMT-130 remains strong and compelling, indicating significant potential for disease modification, which is unprecedented in Huntington’s disease treatment. This potential, combined with the lack of existing disease-modifying therapies for patients, underscores the importance of AMT-130.
Moreover, Schwartz highlights uniQure’s proactive engagement with the Huntington’s disease community, including patient advocacy groups and healthcare stakeholders. The company’s active involvement and strategic positioning with key organizations and centers of excellence demonstrate their commitment to a successful launch of AMT-130. The positive feedback from both physicians and patients further supports the high unmet need and enthusiasm surrounding the therapy, reinforcing Schwartz’s confidence in the stock’s potential growth and the decision to maintain a Buy rating.
According to TipRanks, Schwartz is a top 100 analyst with an average return of 35.8% and a 54.12% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Insmed, and uniQure.
In another report released on November 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.